Axsome Therapeutics, Inc. reported significant financial results for the second quarter of 2026, with total revenues reaching $218.4 million, a 45.5% increase from $150.0 million in the same period of 2025. For the first half of 2026, revenues totaled $409.6 million, compared to $271.5 million for the first half of 2025. The growth in revenue was primarily driven by increased product sales, particularly from AUVELITY, which generated $180.3 million in the second quarter, up from $119.6 million a year earlier. The company also recognized milestone revenues of $0.5 million related to AUVELITY and SUNOSI during the quarter.
Despite the revenue growth, Axsome reported a net loss of $51.3 million for the second quarter of 2026, compared to a net loss of $48.0 million in the same quarter of 2025. The increase in losses was attributed to higher selling, general, and administrative expenses, which rose to $208.1 million from $130.3 million year-over-year, largely due to pre-launch activities for AUVELITY's new indication for agitation associated with dementia due to Alzheimer’s disease, as well as increased marketing efforts for SYMBRAVO.
Operationally, Axsome has expanded its commercial infrastructure, now employing 1,346 full-time staff as of August 3, 2026. The company has also made strategic acquisitions, including the global rights to AXS-20, a selective PDE10A inhibitor for schizophrenia, and AXS-17, a GABAA receptor modulator for epilepsy. These acquisitions are part of Axsome's strategy to enhance its pipeline of CNS therapies, which includes several products currently in various stages of clinical development.
Looking ahead, Axsome anticipates continued revenue fluctuations based on market demand for its products. The company believes its existing cash reserves, totaling approximately $319.9 million as of June 30, 2026, will be sufficient to fund operations for at least the next twelve months. However, management has indicated that additional financing may be necessary to support ongoing clinical trials and commercialization efforts. The company remains focused on achieving profitability, although it acknowledges the challenges posed by ongoing operating losses and the competitive landscape in the biopharmaceutical industry.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel oral therapies for central nervous system (CNS) disorders. Its portfolio includes FDA-approved products for major depressive disorder, excessive daytime sleepiness, and acute migraine treatment, alongside late-stage candidates for Alzheimer’s agitation, narcolepsy, fibromyalgia, and other CNS conditions. Axsome leverages proprietary formulation technologies and targets underserved CNS markets with high unmet medical needs, primarily serving patients and healthcare providers in the U.S.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov